Brooks Laboratories Limited is a pharmaceutical manufacturing company. The Company is engaged in manufacturing of drugs and pharmaceuticals. The Company is a contract manufacturing company for molecules in Injectables and Clavulanic Acid range in tablets and dry syrups. The Company has a range of products catering to critical care segment in parental section, such as Beta Lactam, Cephalosporin and General dry powder Injectables, Ampoules and Liquid vials. Its products include Ampicillin Sodium Injection, Aztreonam for Injection, Cefixime Tablets, Cefixime Oral Suspension, Cefpodoxime Proxetil Tablets, Cefuroxime Axetil Tablets, Cefuroxime Axetil for Oral Suspension, Cefoperazone Injection, Ceftriaxone Injection, Ceftazidime for Injection, Cefuroxime Injection, Meropenem Injection, Doripenem Injection, Aciclovir Intravenous Infusion, Artesunate Injection, Pantoprazole Sodium for Injection and Azithromycin for Injection. It has set up a manufacturing plant at Baddi, Himachal Pradesh.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.